N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice

Documenti analoghi

• N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
  di: Baek, R, et al.
  Pubblicazione: (2008)
• Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice
  di: Baek, R, et al.
  Pubblicazione: (2005)
• N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
  di: Kasperzyk, J, et al.
  Pubblicazione: (2004)
• N-butyldeoxygalactonojirimycin reduces postnatal cerebellar ganglioside content in a mouse model of GM1 gangliosidosis
  di: Kasperzyk, J, et al.
  Pubblicazione: (2004)
• Substrate deprivation therapy reduces brain ganglioside content and GM1 in neonatal storage disease mice
  di: Kasperzyk, J, et al.
  Pubblicazione: (2002)